CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies.
Jan/2022
CancerAppy closed 2021 with €690K total raised.
Together with our collaborators, we have found a new therapeutic target for TNBCs that we are currently patenting.
Nov/2021
The Ministry of Science and Technology has granted Torres Quevedo research grant for our researcher Elisa Poyatos.
Sep/2021
CancerAppy raised a pre-seed round of € 50K
Sep/2021
Enisa has granted us a loan of 100K
CancerAppy has been selected to participate in the Spanish delegation of the 4YFN 2021 event
Dic/2020
Cancerappy obtained the positive resolution of the Neotec 2020 program.
Oct/2020
CancerAppy was one of the 24 projects selected to exhibit at the B-venture 2020 Bilbao.
Sep/2020
Version 6.0 AI 1.0
AI + Drug Interaction / Personalized Medicine
Apr/2020
Version 5.0
Code rewritten. Drug Interaction
Apr/2020
CancerAppy raised a pre-seed round of € 120K
Dec/2019
Version 4.0
Tested at 6 hospitals and universities
Aug/2019
Cancerappy is founded in Bilbao as a startup